CN107613979A - 响应于雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食（fmd）和降葡萄糖药物保护正常细胞并产生癌症敏感条件 - Google Patents

响应于雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食（fmd）和降葡萄糖药物保护正常细胞并产生癌症敏感条件 Download PDF

Info

Publication number
CN107613979A
CN107613979A CN201680022154.8A CN201680022154A CN107613979A CN 107613979 A CN107613979 A CN 107613979A CN 201680022154 A CN201680022154 A CN 201680022154A CN 107613979 A CN107613979 A CN 107613979A
Authority
CN
China
Prior art keywords
hyperglycemia
subject
method described
chemotherapy
fmd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680022154.8A
Other languages
English (en)
Chinese (zh)
Inventor
瓦尔特·D·隆哥
斯特凡诺·迪比亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CN107613979A publication Critical patent/CN107613979A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201680022154.8A 2015-04-16 2016-04-18 响应于雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食（fmd）和降葡萄糖药物保护正常细胞并产生癌症敏感条件 Pending CN107613979A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (1)

Publication Number Publication Date
CN107613979A true CN107613979A (zh) 2018-01-19

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680022154.8A Pending CN107613979A (zh) 2015-04-16 2016-04-18 响应于雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食（fmd）和降葡萄糖药物保护正常细胞并产生癌症敏感条件

Country Status (14)

Country Link
US (2) US20160303056A1 (https=)
EP (2) EP3283073A4 (https=)
JP (2) JP2018511625A (https=)
KR (1) KR20180002677A (https=)
CN (1) CN107613979A (https=)
AU (1) AU2016248443B2 (https=)
BR (1) BR112017022244A2 (https=)
CA (2) CA2982875C (https=)
HK (1) HK1249858A1 (https=)
IL (1) IL255026A0 (https=)
MX (1) MX2017013133A (https=)
RU (1) RU2734774C2 (https=)
WO (1) WO2016168802A2 (https=)
ZA (1) ZA201707710B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023748A2 (pt) 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CA3134756A1 (en) 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
EP4164407A4 (en) * 2020-06-14 2024-08-28 L-Nutra Inc. BAR/DRINK FOR INTERMITTENT FASTING THAT MAINTAINS AND PROLONGS THE FASTING STATE
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753162A (zh) * 2009-10-22 2012-10-24 南加利福尼亚大学 增加癌症治疗的效力和降低副作用的方法和营养配方
CN103347521A (zh) * 2010-12-06 2013-10-09 全球癌症治疗公司 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) * 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753162A (zh) * 2009-10-22 2012-10-24 南加利福尼亚大学 增加癌症治疗的效力和降低副作用的方法和营养配方
CN103347521A (zh) * 2010-12-06 2013-10-09 全球癌症治疗公司 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHERYL A.KRONE等: "Controlling Hyperglycemia as an Adjunct to Cancer Therapy", 《INTEGRATIVE CANCER THERAPIES 》 *

Also Published As

Publication number Publication date
RU2734774C2 (ru) 2020-10-23
KR20180002677A (ko) 2018-01-08
WO2016168802A2 (en) 2016-10-20
CA3108664A1 (en) 2016-10-20
EP3283073A2 (en) 2018-02-21
RU2017136423A3 (https=) 2019-09-04
JP2018511625A (ja) 2018-04-26
ZA201707710B (en) 2019-04-24
EP4299061A2 (en) 2024-01-03
CA2982875C (en) 2021-10-19
JP2021008491A (ja) 2021-01-28
EP4299061A3 (en) 2024-02-28
HK1249858A1 (zh) 2018-11-16
EP3283073A4 (en) 2019-02-13
IL255026A0 (en) 2017-12-31
BR112017022244A2 (pt) 2018-07-10
AU2016248443B2 (en) 2021-03-18
US20210137856A1 (en) 2021-05-13
US20160303056A1 (en) 2016-10-20
MX2017013133A (es) 2018-09-07
AU2016248443A1 (en) 2017-11-02
RU2017136423A (ru) 2019-05-16
CA2982875A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
CN107613979A (zh) 响应于雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食（fmd）和降葡萄糖药物保护正常细胞并产生癌症敏感条件
CN103260437B (zh) 优化的营养制剂、由其选择定制饮食的方法及其使用方法
KR102811762B1 (ko) 상승된 콜레스테롤 수준 및/또는 상승된 ldl 수준의 감소용 금식 모방 규정식 조성물
RU2549954C2 (ru) Способы и диетологические составы для повышения эффективности и снижения побочных эффектов лечения рака
AU2020200726B2 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CN105008929A (zh) 预防化学毒性和与年龄相关的疾病的方法和膳食
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
US20150250771A1 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
HK40100962A (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
US12285453B2 (en) Fasting-mimicking diet promotes cancer-free survival in acute lymphoblastic leukemia models
HK40002950B (zh) 为受试者提供合理蛋白质膳食的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1249858

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180119

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1249858

Country of ref document: HK